Latest News

Ever wondered if Revolution Medicines is trading at an attractive price, or if investors are getting ahead of themselves? Let's take a closer look at what's been powering curiosity around this biotech stock. Revolution Medicines has gained 2.3% in the past week and jumped an impressive 27.4% over the last month, with the stock up 34.9% year-to-date and a staggering 212.8% over three years. The buzz has only grown following recent reports of successful progress in its...

Qiagen (NYSE:QGEN) reported a sharp turnaround in profitability this quarter, with net profit margins rising to 18.3% from just 3.7% a year ago. Earnings growth surged by 413.6% over the past twelve months. Despite a negative five-year trend, earnings are now forecast to increase at 11.5% per year. This forecast is below the broader US market’s expected pace. Investors will note that Qiagen shares are trading at $44.05, representing a discount to the estimated fair value and pricing in...

Healthcare Realty Trust (HR) just launched a $500 million share buyback program, along with its latest quarterly earnings report. Investors are watching closely as the firm also lowered its 2025 earnings guidance. See our latest analysis for Healthcare Realty Trust. Healthcare Realty Trust’s latest quarter saw a mix of cautious optimism and strategic moves. The firm announced a fresh $500 million share repurchase program and continued its regular dividend. Management also lowered earnings...

Targa Resources (TRGP) delivered annual revenue growth of 4.1%, trailing the broader US market’s 10.5% pace. Net profit margins have risen to 8.9% from 6.5%, highlighting greater operational efficiency. Earnings are forecast to climb 10% per year, which is short of the US market’s 16% annual projection, and the company’s share price currently stands at $162.69, which is below some analyst fair value estimates. While longer-term earnings surged by an average of 62.5% per year over the last...

Empire Company Limited's Board of Directors has named Pierre St-Laurent as President and CEO, following the retirement of Michael Medline after nine years at the helm. St-Laurent's appointment highlights Empire's commitment to internal leadership development, as he brings over three decades of experience spanning key operational and financial roles within the company. We'll explore how St-Laurent's deep operational expertise shapes the future investment narrative for Empire Company...

Avista (AVA) reported a net profit margin of 9.2% for the recent period, which is lower than last year's 10.1%. Over the past five years, the company has delivered average annual earnings growth of 8%. However, results for the most recent year show negative growth, breaking with that trend. Looking ahead, Avista is expected to grow earnings at 9.23% per year and revenue at 3.7% per year, a pace that is slower than the broader US market's forecasted growth. The stock closed at $39.74, above...

Tempus AI (TEM) posted continued losses, with net losses increasing at a rate of 19.6% annually over the past five years and profit margins remaining unimproved during that period. Despite these persistent losses, the company is projected to see earnings grow 62.68% per year and cross into profitability within the next three years. Revenue growth is estimated at 19.1% per year, which is well ahead of the broader US market forecast of 10.4%. See our full analysis for Tempus AI. The next...

Orchid Island Capital recently announced the filing of a US$500 million at-the-market follow-on equity offering and an updated US$80.39 million shelf registration covering common stock, preferred stock, debt securities, warrants, and units. This dual move signals meaningful plans for future capital raising, which can impact dilution prospects and inform investor expectations about the company’s funding and growth strategies. We’ll explore how this significant at-the-market equity offering...

American International Group (AIG) reported net profit margins of 11.9%, a jump from 8% a year earlier, and annual earnings growth of 50.8% dramatically outpacing its five-year average of 8.1% per year. Revenue and earnings are forecast to grow at 4.4% and 0.9% per year respectively, both tracking below broader US market trends. With margins improving and profitability standing out, the company continues to draw investor interest, especially as its valuation sits below the industry average...

If you find yourself wondering whether Fidelity National Financial is a bargain, you are in good company, and this is the right place to get clear answers. While the stock dipped 5.0% over the past month and is down 6.3% over the past year, long-term investors have still seen impressive gains of 104.6% over five years. Recent headlines have highlighted Fidelity National Financial's continued expansion in the title insurance space, along with strategic moves that have caught investors’...

In the midst of a volatile U.S. market, where concerns about AI valuations have led to fluctuations in major indices like the Dow Jones and Nasdaq, investors are closely watching earnings reports and economic indicators amid a historic government shutdown. As tech stocks face renewed scrutiny, identifying high-growth opportunities requires careful consideration of companies' adaptability to current trends and their potential for innovation in an uncertain economic landscape.

As the U.S. stock market grapples with AI valuation concerns and fluctuating index performances, investors are keenly assessing earnings reports for guidance. Amid these broader market dynamics, penny stocks—despite their somewhat outdated moniker—remain a compelling area of interest for those seeking opportunities in smaller or newer companies. By focusing on firms with solid financial foundations, investors can uncover potential value and growth prospects that larger companies may overlook.

Earlier this week, Berry Genomics announced that its Sequel II CNDx system, developed with Pacific Biosciences, received China's first Class III medical device approval for clinical-grade long-read sequencing, enabling full-scale genomic workflows for thalassemia and rare disease testing in hospitals and labs. This regulatory milestone opens up access to precision genomic diagnostics across China, an area where complex variant detection has previously been limited by short-read...

Humana (HUM) posted a softer set of headline numbers this cycle, with revenue projected to advance 7.1% per year, lagging the broader US market’s anticipated 10.4%. EPS has taken a hit, declining by 17.2% per year over the past five years, and net profit margins dipped from 1.5% to 1.3%. Yet, the outlook has flipped: forward estimates call for annual earnings growth of 26.9%, which is well ahead of the US market average of 15.8%. Meanwhile, the shares are trading below estimated fair value...

Plains All American Pipeline (PAA) posted a net profit margin of 1% for the twelve months through September 30, 2025, notably below last year’s 1.5%, as results absorbed a one-off loss of $485 million. After five years of strong profitability and a 50.6% average annual earnings growth, the trend reversed with negative earnings growth this year. Management now expects earnings to rise just 4.4% per year, which is well below the US market average of 15.8%. With revenue projected to dip slightly...

Wondering if Honest Company stock is a smart buy at this price? Let’s dive into what recent numbers and real trends are telling us about its true value. The stock has seen a notable drop lately, falling 16.9% over the past month and 51.4% year-to-date. This has sparked new questions about its growth outlook and the risks investors may be seeing. Recent headlines suggest Honest Company is exploring new product launches and expanding its retail partnerships. These moves could reshape its...

Ternium S.A. recently reported third quarter 2025 earnings, noting sales of US$3,955 million and net income of US$21 million, alongside the approval of an interim dividend of US$0.90 per ADS to be paid in November. While quarterly sales and net income declined year-over-year, the company returned to profitability over the nine-month period and maintained shareholder distributions through its dividend declaration. To better understand the implications of Ternium’s continued dividend payout...

Despite an already strong run, Victoria's Secret & Co. ( NYSE:VSCO ) shares have been powering on, with a gain of 28...

Ever wonder if Lionsgate Studios stock is a hidden gem or just another name in entertainment? Let’s break down what might make it a compelling buy or not right now. The share price has climbed 8.2% over the past week and is up 4.8% for the month, bouncing back despite a YTD slip of 14.2% and a one-year gain of 6%. Industry buzz has been stirred by recent strategic studio partnerships and growing interest in Lionsgate's expanding streaming catalog. This has fueled speculation that the...

Payoneer Global (PAYO) posted a forecasted annual earnings growth of 27.1%, outpacing the broader US market's expected 16% rise. However, revenue is projected to climb at 8.8% per year, slightly behind the US market average of 10.5%. The company’s net profit margin came in at 9.8%, lower than last year’s 11.2%, which points to tightening profitability even as earnings momentum remains strong. Over the past five years, Payoneer has averaged 74.3% annual earnings growth, but the stock now...

Middlesex Water Company recently reported third quarter 2025 earnings showing net income of US$13.96 million on sales of US$54.09 million, alongside a declared quarterly dividend increase to US$0.36 per share. This marks the company's 53rd consecutive year of raising dividends, underlining its continued emphasis on returning value to shareholders despite slightly lower earnings compared to the previous year. We'll explore how the latest dividend increase shapes Middlesex Water's broader...

ProAssurance (PRA) has swung to profitability over the past five years, reporting an annual earnings growth rate of 37.3% and showing improved profit margins in its most recent results. Forward-looking projections see earnings climbing a further 20.7% per year, notably outpacing the broader US market expectation of 16% growth, even though revenue is anticipated to edge down by 1.6% per year. With high-quality earnings and persistent profit momentum, investor focus will be on whether strong...

National Vision Holdings (EYE) has deepened its unprofitable streak, with losses compounding at a brisk 56.1% per year over the last five years and a net profit margin that remains in the red, showing no improvement in the past year. Despite the persistent losses, there is a bright spot: earnings are forecast to grow 20.57% annually, and the company is expected to reach profitability within three years, a turnaround rate that is ahead of most in the market. Revenue prospects are more muted,...

Curious if Iovance Biotherapeutics might be deeply undervalued, or if there's a catch behind the low share price? You're not alone. We're diving straight into what might be driving investor interest right now. The stock has had a rough ride, losing 9.5% in the past week and a staggering 85.1% over the last year, so there’s no denying that volatility and risk perception are front of mind for investors. Recently, clinical trial updates related to Iovance’s cancer immunotherapy platform and...